BPC-157 is a synthetic peptide of 15 amino acids, based on a fragment of a protective protein from human gastric juice. In animal studies it accelerated healing of tendons, muscle and the gastric lining. Human data are minimal: one small observational study and no randomised trials.
BPC-157 is not an approved medicine and it is banned in sport. This article separates what has been shown in animals from what has been tested in people. Where BPC-157 sits among other recovery peptides is covered in our pillar article on how recovery peptides work.
What is BPC-157?
BPC-157 stands for body protection compound. The peptide consists of 15 amino acids and corresponds to a fragment of a larger protein isolated from gastric juice. It acts as a signalling molecule and may trigger several repair pathways at once. It is sold as a lyophilised powder, as research material.
What did animal studies of BPC-157 show?
Most of the data on BPC-157 come from studies in rats and from cell cultures. Under those conditions the peptide accelerated healing of a transected Achilles tendon, of damaged muscle and of ligaments, and it protected the gastric lining. The mechanisms described include formation of new blood vessels, collagen synthesis and activation of fibroblasts.
These results are promising, but they concern animal models. Transferring them directly to a clinical situation in humans calls for caution, because doses, routes of administration and the course of healing all differ.
What do human studies of BPC-157 show?
Human data amount to one small observational study. In a retrospective analysis from 2021 covering 16 people, roughly 92% of patients reported improvement in various types of knee pain after an injection of BPC-157 into the joint. The study ran at a single centre with a single investigator, and the assessment rested on patient-reported sensations rather than measurements.
No randomised trials have been carried out. A phase 1 safety study was discontinued before its results passed quality review. The only earlier human safety data come from a study on inflammatory bowel disease conducted in Croatia in the early 2000s. The clinical safety of BPC-157 in humans remains largely unknown.
Is BPC-157 safe?
No human data confirm that it is. In animal studies no lethal or toxic dose was established and no organ damage was observed, but animal results do not replace clinical trials. The level of evidence for BPC-157 is rated as low.
Is BPC-157 legal?
BPC-157 is not approved by the United States Food and Drug Administration for any indication. The World Anti-Doping Agency classes it as prohibited at all times, both in and out of competition.
In our shop BPC-157 appears only as research material: BPC-157 5 mg and a BPC-157 and TB-500 blend. The cart and the checkout are in English and prices are shown in Polish zloty. How the two peptides differ is covered in the article on TB-500 compared with BPC-157.
Frequently asked questions
How many human studies of BPC-157 are there?
One small observational study on knee pain, plus older data from a study on inflammatory bowel disease. There are no randomised trials and no large clinical trials.
Where does BPC-157 come from?
It corresponds to a fragment of a protein isolated from gastric juice. BPC-157 itself is produced synthetically and consists of 15 amino acids.
Does BPC-157 speed up tendon healing in humans?
That has not been demonstrated in clinical trials. Data on the effect of BPC-157 on muscle and tendon healing are limited to studies in rats and cell cultures.
Can BPC-157 be used in sport?
It cannot. The peptide is on the World Anti-Doping Agency prohibited list at all times.
Is BPC-157 an approved medicine anywhere?
No. It holds no approval for any indication from the United States Food and Drug Administration, and it is not a registered medicine in the European Union.
Where this information comes from
The description of BPC-157, the predominance of animal data and its status with the United States Food and Drug Administration come from material published by Maryland Orthopedic Specialists. The human study data come from a review by inPharmD: one 2021 study on 16 people with roughly 92% improvement in knee pain, no randomised trials, a discontinued phase 1 study, the earlier Croatian study and the low level of evidence. Both pages were checked on 31 August 2026.